‘Early treatment initiation’ key to drug-free remission in axial spondyloarthritis

DESTIN, Fla. — Early treatment can provide patients with axial spondyloarthritis a better opportunity to achieve drug-free remission and slow disease progression, according to a speaker at the Congress of Clinical Rheumatology East 2022.
Specifically, Janus kinase inhibitors such as tofacitinib (Xeljanz, Pfizer), upadacitinib (Rinvoq, AbbVie) and filgotinib (Gilead Sciences/ Galapagos NV) have demonstrated capacity to reduce spine and sacroiliac joint inflammation as measured by MRIs, said Nigel Haroon, MD, PhD, DM, MBA, FRCPC, head of the rheumatology department at the University Health

DESTIN, Fla. — Early treatment can provide patients with axial spondyloarthritis a better opportunity to achieve drug-free remission and slow disease progression, according to a speaker at the Congress of Clinical Rheumatology East 2022.
Specifically, Janus kinase inhibitors such as tofacitinib (Xeljanz, Pfizer), upadacitinib (Rinvoq, AbbVie) and filgotinib (Gilead Sciences/ Galapagos NV) have demonstrated capacity to reduce spine and sacroiliac joint inflammation as measured by MRIs, said Nigel Haroon, MD, PhD, DM, MBA, FRCPC, head of the rheumatology department at the University Health